| Subject: | FDA Issues Public Health Advisory About Suspended Marketing of Tysabri (Natalizumab) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 8 Mar 2005 - 10:00 am |
| The FDA has issued a Public Health Advisory regarding suspended marketing of the drug Tysabri (natalizumab), manufactured by Biogen, Idec. Tysabri is prescribed for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. The FDA issued the Public Health Advisory notifying healthcare providers that Biogen Idec voluntarily suspended marketing of Tysabri due to reports of one fatal case and one possible case of multifocal... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|